List of Aplenzin drug patents
Aplenzin is owned by Bausch.
Aplenzin contains Bupropion Hydrobromide.
Aplenzin has a total of 8 drug patents out of which 0 drug patents have expired.
Aplenzin was authorised for market use on 23 April, 2008.
Aplenzin is available in tablet, extended release;oral dosage forms.
Aplenzin can be used as treatment of major depressive disorder by dosing at intervals of 24 hours.
The generics of Aplenzin are possible to be released after 27 June, 2026.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7569610 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(3 years from now) | |
| US7585897 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(3 years from now) | |
| US7572935 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(3 years from now) | |
| US7662407 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(3 years from now) | |
| US7645802 | BAUSCH | Bupropion hydrobromide and therapeutic applications |
Jun, 2026
(3 years from now) | |
| US7671094 | BAUSCH | Bupropion hydrobromide and therapeutic applications |
Jun, 2026
(3 years from now) | |
| US7649019 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(3 years from now) | |
| US7241805 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(3 years from now) | |
Drugs and Companies using BUPROPION HYDROBROMIDE ingredient
Market Authorisation Date: 23 April, 2008
Treatment: Treatment of major depressive disorder by dosing at intervals of 24 hours
Dosage: TABLET, EXTENDED RELEASE;ORAL
APLENZIN family patents
24
United States
8
European Union
4
Canada
3
Russia
3
China
3
Korea, Republic of
3
South Africa
3
Japan
3
Australia
2
Costa Rica
2
Colombia
2
New Zealand
2
Mexico
2
Nicaragua
2
Ecuador
1
Singapore
1
Ireland
1
Hong Kong
1
Israel
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic